Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

Alphamab Oncology’s JSKN033 Gets Green Light for Phase I/II Study from China’s CDE

Fineline Cube Dec 25, 2024

China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...

Company Drug

CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment

Fineline Cube Dec 24, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...

Company Drug

Keymed Biosciences’ Kangyueda Approved for CRSwNP Treatment in China

Fineline Cube Dec 24, 2024

China-based Keymed Biosciences Inc., (HKG: 2162) has announced that it has received another indication approval...

Company Drug

Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases

Fineline Cube Dec 24, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Drug

Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial

Fineline Cube Dec 24, 2024

China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green...

Company Drug

AstraZeneca’s Tagrisso Secures EU Approval for EGFR-Mutated Locally Advanced NSCLC

Fineline Cube Dec 24, 2024

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that the European Commission (EU) has...

Company Deals

Ikena Oncology and Inmagene Biopharmaceuticals to Merge into ImageneBio, Listed on Nasdaq as ‘IMA’

Fineline Cube Dec 24, 2024

US-based Ikena Oncology, Inc. (NASDAQ: IKNA) and Sino-US biotech Inmagene Biopharmaceuticals have announced their merger...

Company Deals

Sanofi and SK bioscience Broaden Partnership to Develop Next-Gen Pneumococcal Vaccines

Fineline Cube Dec 24, 2024

French pharmaceutical major Sanofi (NASDAQ: SNY) and South Korea-based SK bioscience (KRX: 302440) have announced...

Company Deals

Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage

Fineline Cube Dec 24, 2024

China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing...

Company Drug

ETERN Therapeutics’ YAP/TEAD Inhibitor ETS-006 Wins FDA Clinical Approval for Advanced Solid Tumors

Fineline Cube Dec 24, 2024

China-based biopharmaceutical company ETERN Therapeutics has announced that it has received clinical approval from the...

Company Drug

Bristol-Myers Squibb’s Opdivo-Yervoy Combo Approved by EC for MSI-H/mCRC

Fineline Cube Dec 24, 2024

Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that it has received marketing...

Company Drug

Roche’s Lunsumio Receives NMPA Approval for R/R Follicular Lymphoma Treatment

Fineline Cube Dec 24, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received marketing approval from...

Company

BeiGene Rebrands to BeOne Medicines Ltd, Ticker Symbol Changes to “ONC”

Fineline Cube Dec 24, 2024

China-based BeiGene Ltd, listed on Nasdaq (NASDAQ: BGNE, HKG: 6160, SHA: 688235), has announced a...

Company Deals

RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904

Fineline Cube Dec 24, 2024

US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the...

Company Deals

Porton Pharma and Dragon Sail Join Forces to Enhance ADC Drug Development

Fineline Cube Dec 24, 2024

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has entered into a strategic...

Company Drug

GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial

Fineline Cube Dec 23, 2024

UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44...

Company Drug

Pfizer’s Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment

Fineline Cube Dec 23, 2024

US-based Pfizer (NYSE: PFE) has announced receiving an indication extension approval from the US Food...

Company Drug

Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity

Fineline Cube Dec 23, 2024

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has revealed that the US Food...

Company Drug

Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis

Fineline Cube Dec 23, 2024

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced that the US Food and Drug Administration...

Company

Boehringer Ingelheim-SEC Joint Incubator Launches in Shenzhen’s Luohu District

Fineline Cube Dec 23, 2024

On December 23, the Boehringer Ingelheim-SEC Joint innovative incubator was inaugurated in Luohu District, Shenzhen....

Posts pagination

1 … 292 293 294 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.